María Jesús Ortiz-Ruiz

Expression of Erk5 in Early Stage Breast Cancer and Association with Disease Free Survival Identifies this Kinase as a Potential Therapeutic Target

Juan Carlos Montero, Alberto Ocaña, Mar Abad et al. · PLoS ONE · 2009 · 103 citations · Full text

Medicine, Cancer Biology, Oncology +15

De Novo Missense Substitutions in the Gene Encoding CDK8, a Regulator of the Mediator Complex, Cause a Syndromic Developmental Disorder

Eduardo Calpena, Alexia Hervieu, Teresa Kaserer et al. · The American Journal of Human Genetics · 2019 · 63 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

Therapeutic potential of ERK5 targeting in triple negative breast cancer

María Jesús Ortiz-Ruiz, Stela Álvarez-Fernández, Tracy Parrott et al. · Oncotarget · 2014 · 48 citations · Full text

Medicine, Oncology, Pharmacology +17

Potent Antimyeloma Activity of a Novel ERK5/CDK Inhibitor

Stela Álvarez-Fernández, María Jesús Ortiz-Ruiz, Tracy Parrott et al. · Clinical Cancer Research · 2013 · 48 citations

Medicine, Oncology, Pharmacology +16

Abstract P4-08-02: LOXO-783: A potent, highly mutant selective and brain-penetrant allosteric PI3Kα H1047R inhibitor in combination with standard of care (SOC) treatments in preclinical PI3Kα H1047R-mutant breast cancer models

Loredana Puca, Michele Dowless, Carmen M. Perez-Ferreiro et al. · Cancer Research · 2023 · 10 citations

Medicine, Oncology, Pharmacology +15